Electroacupuncture for control of myeloablative chemotherapy-induced emesis - A randomized controlled trial

被引:215
作者
Shen, JN
Wenger, N
Glaspy, J
Hays, RD
Albert, PS
Choi, C
Shekelle, PG
机构
[1] NIAAA, Clin Studies Lab, Brain Electrophysiol & Imaging Sect, NIH, Bethesda, MD 20892 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA
[3] Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90024 USA
[4] RAND Corp, Santa Monica, CA USA
[5] NCI, Biometr Res Branch, NIH, Bethesda, MD 20892 USA
[6] W Los Angeles Vet Affairs Med Ctr, Dept Med, Vet Affairs Hlth Serv REs & Dev Serv, Los Angeles, CA 90073 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 284卷 / 21期
关键词
D O I
10.1001/jama.284.21.2755
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context High-dose chemotherapy poses considerable challenges to emesis management. Although prior studies suggest that acupuncture may reduce nausea and emesis, it is unclear whether such benefit comes from the nonspecific effects of attention and clinician-patient interaction. Objective To compare the effectiveness of electroacupuncture vs minimal needling and mock electrical stimulation or antiemetic medications alone in controlling emesis among patients undergoing a highly emetogenic chemotherapy regimen. Design Three-arm, parallel-group, randomized controlled trial conducted from March 1996 to December 1997, with a 5-day study period and a 9-day follow-up. Setting Oncology center at a university medical center. Patients One hundred four women (mean age, 46 years) with high-risk breast cancer. Interventions Patients were randomly assigned to receive low-frequency electroacupuncture at classic antiemetic acupuncture points once daily for 5 days (n=37), minimal needling at control points with mock electrostimulation on the same schedule (n=33); or no adjunct needling (n=34). All patients received concurrent triple antiemetic pharmacotherapy and high-dose chemotherapy (cyclophosphamide, cisplatin, and carmustine). Main Outcome Measures Total number of emesis episodes occurring during the 5-day study period and the proportion of emesis-free days, compared among the 3 groups. Results The number of emesis episodes occurring during the 5 days was lower for patients receiving electroacupuncture compared with those receiving minimal needling or pharmacotherapy alone (median number of episodes, 5, 10, and 15, respectively; P<.001). The electroacupuncture group had fewer episodes of emesis than the minimal needling group (P<.001), whereas the minimal needling group had fewer episodes of emesis than the antiemetic pharmacotherapy alone group (P=.01), The differences among groups were not significant during the 9-day follow-up period (P=.18), Conclusions in this study of patients with breast cancer receiving high-dose chemotherapy, adjunct electroacupuncture was more effective in controlling emesis than minimal needling or antiemetic pharmacotherapy alone, although the observed effect had limited duration.
引用
收藏
页码:2755 / 2761
页数:7
相关论文
共 31 条
[1]   A PILOT-STUDY OF METOCLOPRAMIDE, DEXAMETHASONE, DIPHENHYDRAMINE AND ACUPUNCTURE IN WOMEN TREATED WITH CISPLATIN [J].
AGLIETTI, L ;
ROILA, F ;
TONATO, M ;
BASURTO, C ;
BRACARDA, S ;
PICCIAFUOCO, M ;
BALLATORI, E ;
DELFAVERO, A .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 26 (03) :239-240
[2]   EFFECTS OF ELECTROACUPUNCTURE AND PHYSICAL EXERCISE ON REGIONAL CONCENTRATIONS OF NEUROPEPTIDES IN RAT-BRAIN [J].
BUCINSKAITE, V ;
LUNDEBERG, T ;
STENFORS, C ;
EKBLOM, A ;
DAHLIN, L ;
THEODORSSON, E .
BRAIN RESEARCH, 1994, 666 (01) :128-132
[3]   Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics [J].
Cagnoni, PJ ;
Matthes, S ;
Day, TC ;
Bearman, SI ;
Shpall, EJ ;
Jones, RB .
BONE MARROW TRANSPLANTATION, 1999, 24 (01) :1-4
[4]  
CHENG RSS, 1989, SCI BASES ACUPUNCTUR, P119
[5]  
DUNDEE JW, 1987, LANCET, V1, P1083
[6]   ACUPUNCTURE PROPHYLAXIS OF CANCER CHEMOTHERAPY-INDUCED SICKNESS [J].
DUNDEE, JW ;
ABRAM, WP ;
GHALY, RG ;
LYNCH, GA ;
FITZPATRICK, KTJ .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1989, 82 (05) :268-271
[7]  
EPSTEIN BS, 1993, HDB NAUSEA VOMITING, P93
[8]   Ondansetron: Reasons to be restrictive [J].
Frigerio, C ;
Burchwalder, PA ;
Spertini, F .
LANCET, 1996, 347 (9013) :1484-1485
[9]   Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer [J].
Gilbert, CJ ;
Petros, WP ;
Vredenburgh, J ;
Hussein, A ;
Ross, M ;
Rubin, P ;
Fehdrau, R ;
Cavanaugh, C ;
Berry, D ;
McKinstry, C ;
Peters, WP .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (06) :497-503
[10]   Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines [J].
Gralla, RJ ;
Osoba, D ;
Kris, MG ;
Kirkbride, P ;
Hesketh, PJ ;
Chinnery, LW ;
Clark-Snow, R ;
Gill, DP ;
Groshen, S ;
Grunberg, S ;
Koeller, JM ;
Morrow, GR ;
Perez, EA ;
Silber, JH ;
Pfister, DG .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2971-2994